Starpharma Holdings Ltd has released a press release.
Starpharma completes oversubscribed A$45M placement
Filed with ASX ·
6ix hasn’t read this filing yet.
Starpharma Holdings Limited on 6ix
In the deck
Earlier from Starpharma
- SPL7013 COVID-19 nasal spray virucidal against SARS-CoV-2
- Starpharma awarded $1M MRFF funding for COVID-19 spray
- SPL creates slow release soluble DEP remdesivir nanoparticle
- SPL7013 nasal spray for COVID19 development update
- Starpharma signs new DEP partnership with Chase Sun
Later from Starpharma
- Share Purchase Plan offer document
- Starpharma receives $5.7M R&D tax incentive refund
- Completion of Placement and SPP raises $48.9M in total
- SPL7013 shows potent antiviral activity in RSV
- VIRALEZE COVID-19 nasal spray to be ready for market Q1CY21
Follow Starpharma into a list and get an email when it puts out news.
Follow Starpharma